Director, Global Value & Access Strategy, povetacicept

Job Description

Director, Global Value Access & Strategy, povetacicept

Location: Boston, MA (3 days onsite, 2 days remote weekly)

Vertex operates at the forefront of scientific innovation and has successfully developed and commercialized multiple breakthrough medicines for Cystic Fibrosis (CF) as well as Casgevy, a gene therapy for sickle cell disease and beta-thalassemia. Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases including programs in Pain, APOL-1 mediated kidney disease (AMKD), and cell therapies for Type 1 diabetes, among others.

Povetacicept is a highly potent and effective dual antagonist of BAFF and APRIL pathways with potential best-in-class efficacy in patients with IgA nephropathy (IgAN) and primary membranous nephropathy (pMN).  IgAN is a serious, progressive, autoimmune disease of the kidney that can lead to end-stage-renal disease. There are no approved therapies that target the underlying cause of IgAN. IgAN is the most common cause of primary (idiopathic) glomerulonephritis worldwide.  Due to its mechanism of action as a dual BAFF/APRIL antagonist, povetacicept holds the potential to benefit patients for multiple serious diseases including other autoimmune kidney diseases and autoimmune cytopenias.

Vertex is expanding its Global Value and Access Strategy (GVAS) team to support the launch of this exciting product. Market Access is a key commercial function that ensures transformative Vertex therapies are appropriately funded and ultimately make it into the hands of the patients around the world. GVAS works cross-functionally and across regions to ensure the payer view is represented in commercial and development plans across the lifecycle. We are driven by a desire to deliver groundbreaking pricing & reimbursement solutions to allow our medicines to reach patients faster than ever before.

The Director, Global Value & Access Strategy, povetacicept role will support the asset with a primary focus on pMN and life cycle management (LCM). In this capacity, the individual will be responsible for launch readiness for the pMN indication including the global price & access strategy and value communications.  This individual will also directly contribute to the life-cycle strategy for the asset, ensuring price and access success. This role will also be accountable for leadership of cross-portfolio capability building and thought leadership projects that advance knowledge of and readiness for the rapidly evolving Global payer environment. The role reports to Global Value & Access Strategy Lead, povetacicept.

Key Responsibilities:

• Ensure launch readiness for pMN indication:
  • Partner cross-functionally and cross-Regionally to ensure robust, differentiated value proposition and integrated evidence plans to support global market access and value
  • Develop of the global pricing and market access strategy, payment models and negotiation approach
  • Lead development of global strategic payer plan and evidence prioritization in the evidence generation plan
  • Drive delivery of unbranded, branded payer value communications and supportive training
• Life-cycle management:
  • Partner cross functionally to shape LCM strategy, including indication sequencing
  • Identify, prioritize and champion evidence required for access enabling trials and value optimization; determine minimum reimbursable profiles
• Accountable for ensuring the market access and payer perspective is reflected in cross-functional strategies (e.g. commercial, product development, regulatory affairs)
• Collaborate closely with HEOR, regional market access, global commercial strategy, clinical development, medical affairs and corporate affairs counterparts to ensure value & access optimization
• Maintain industry awareness and proactively address changes in market trends, competition, product acceptance and new product releases and adjust market access plans accordingly